Here is the design of a clinical trial:

Official Title: The Timing of Continuous Renal Replacement Therapy Initiation in Sepsis-associated Acute Kidney Injury in the Intensive Care Unit

Included conditions:
- Sepsis-Associated Organ Dysfunction
- RTT

Study Armgroups:
- {'label': 'early group', 'type': 'EXPERIMENTAL', 'description': 'In the early group, continuous renal replacement therapies was started within 8 hours after randomization.', 'interventionNames': ['Procedure: continuous renal replacement therapies']}
- {'label': 'delayed group', 'type': 'EXPERIMENTAL', 'description': 'In the delayed group, continuous renal replacement therapies was initiated if at least one of the following criteria was met: KDIGO 3, severe hyperkalemia, pulmonary edema, blood urea nitrogen level higher than 112 mg per deciliter after randomization.', 'interventionNames': ['Procedure: continuous renal replacement therapies']}

Interventions:
- {'type': 'PROCEDURE', 'name': 'continuous renal replacement therapies', 'description': 'The choice of the method of continuous renal replacement therapy (device setting and anticoagulation method) is left to the discretion of each study site and was prescribed and monitored according to national guidelines.', 'armGroupLabels': ['delayed group', 'early group']}

Primary Outcomes:
- {'measure': 'overall mortality', 'description': 'overall survival measured from randomization to death or day 90', 'timeFrame': '90 days'}

Please estimate the sample size based on the assumption: 
Differences between the two groups will be detected with a power of 85% at a bilateral α risk of 0.05. The rate of non-evaluable cases is expected to be 15%.
Sample size
        The primary end point in this study is to compare the effect of early and delayed CRRT strategy on overall survival at day 90 in patients with SAKI. Our primary hypothesis is that the early CRRT strategy might beneficial to patients with SAKI. According to the IDEAL-ICU Study, the expected mortality of patients with SAKI in the delayed group may be estimated around 55%. Considering that the timing setting of CRRT in this study is similar to the ELAIN Study, a reduction in mortality of 15% in the early group (55% mortality in the delayed CRRT group vs 40% in the early CRRT group) can be expected. Differences between two groups will be detected with a power of 85% at a bilateral Î± risk of 0.05. Considering that in China, some patients will give up treatment and request discharge from hospital due to economic reasons or customs, the rate of non-evaluable cases is expected to be 15% for the worst. Hence, a total of 460 patients (230 per group) is required. Power calculations were performed using the Power Analysis & Sample Size (PASS) V.14.0 software.